For the Quarter Ending June 2026
Ivermectin Prices in North America
- In the United States, Ivermectin Price Index rose in Q2 2026, driven by rising production costs and robust demand.
- Ivermectin production costs increased as PPI rose 5.5% year-over-year in June 2026.
- Demand for Ivermectin was supported by retail sales, which grew 6.9% year-over-year in May 2026.
- Despite 3.5% CPI rise year-over-year in June 2026, consumer confidence remained moderate.
- Unemployment rate remained low at 4.2% in June 2026, supporting consumer income and affordability.
- Industrial production grew 0.7% year-over-year in June 2026, indicating slower overall economic activity.
- Natural gas prices at Henry Hub decreased in April 2026, offering relief to production costs.
- Retail electricity revenues per kilowatt-hour increased in April 2026, impacting manufacturing expenses.
- New U.S. trade measures influenced pharmaceutical supply chains in Q2 2026, prompting diversification.
Why did the price of Ivermectin change in June 2026 in North America?
- Production costs rose due to 5.5% PPI increase year-over-year in June 2026.
- Demand supported by 4.2% unemployment rate and 91.2 consumer confidence in June 2026.
- US healthcare spending strengthened in Q2 2026, boosting demand for medical goods.
Ivermectin Prices in APAC
- In China, the Ivermectin Price Index rose quarter-over-quarter in Q2 2026, driven by increasing production costs.
- Ivermectin production costs increased in Q2 2026, influenced by a 4.1% rise in PPI year-over-year in June 2026.
- Weak consumer demand, with retail sales growing only 1.0% year-over-year in June 2026, impacted Ivermectin demand.
- The average FOB price of Ivermectin in China was USD 98000/MT.
- Feedstock and chemical raw material costs increased in Q2 2026, raising Ivermectin manufacturing expenses.
- China's Manufacturing Index expanded in June 2026, indicating a supportive industrial environment for Ivermectin production.
- Industrial production grew 5.3% year-over-year in June 2026, bolstering the supply chain for Ivermectin inputs.
- Chemical exports from China achieved counter-cyclical growth in Q2 2026, leveraging production capacity and cost advantages.
Why did the price of Ivermectin change in June 2026 in APAC?
- Ivermectin production costs rose from a 4.1% PPI increase year-over-year in June 2026.
- Weak consumer demand, 1.0% retail sales growth in June 2026, tempered Ivermectin price increases.
- Rising chemical raw material and feedstock costs in Q2 2026 exerted upward pressure.
Ivermectin Prices in Europe
- In Germany, the Ivermectin Price Index rose quarter-over-quarter in Q2 2026, driven by sharply climbing input costs.
- Ivermectin production costs increased significantly in Q2 2026, influenced by a 2.2% rise in producer prices in May 2026.
- Weak domestic and European demand for Ivermectin persisted in Q2 2026, with consumer confidence declining to -14.6% in June 2026.
- Precautionary inventory builds occurred in Q2 2026, leading to short-term sales upticks, but buyers planned lean inventories.
- German chemical sector exports declined in the first half of 2026, as industrial production remained unchanged at 0.0% in May 2026.
- High energy prices and a 2.3% CPI rise in June 2026 pressured operational costs, impacting Ivermectin profitability.
- Retail sales increased by 1.8% in May 2026, while unemployment remained stable at 3.8% in May 2026.
- The Ivermectin Price Index is forecast to face continued upward pressure due to rising chemical input costs in Q2 2026.
Why did the price of Ivermectin change in June 2026 in Europe?
- Producer prices for industrial products rose by 2.2% in May 2026, increasing Ivermectin manufacturing costs.
- High energy prices, including surging electricity in May 2026, exerted significant pressure on production expenses.
- Weak domestic and European demand for Ivermectin persisted in Q2 2026, limiting upward price momentum.
For the Quarter Ending March 2026
Ivermectin Prices in North America
- In United States, the Ivermectin Price Index rose quarter-over-quarter in Q1 2026, reflecting elevated production costs.
- The Producer Price Index rose 4.0% in March 2026, increasing the Ivermectin Production Cost Trend.
- Consumer inflation reached 3.3% and retail sales grew 4.0% in March 2026, supporting Ivermectin Demand Outlook.
- Industrial production grew 0.7% and the Manufacturing Index expanded in March 2026, tightening formulation material availability.
- Unemployment stabilized at 4.3% and consumer confidence reached 91.8 in March 2026, sustaining companion animal demand.
- Emergency veterinary demand surged following a federal emergency use authorization for injectable formulations in February 2026.
- Costs for synthesis solvent methanol strengthened while natural gas feedstock costs rose during Q1 2026.
- Conversely, fermentation feedstock sugar weakened in March 2026 and nutrient soybean meal declined in January 2026.
- The national cattle herd contracted and live cattle imports remained restricted in January 2026.
- The Ivermectin Price Forecast indicated upward pressure in Q1 2026 due to tightening domestic solvent inventories.
Why did the price of Ivermectin change in March 2026 in North America?
- Synthesis solvent methanol costs strengthened and domestic inventories drew down significantly during Q1 2026.
- Emergency veterinary demand for injectable formulations surged following federal emergency use authorizations in February 2026.
- The Producer Price Index increased 4.0% in March 2026, elevating energy-intensive pharmaceutical manufacturing expenses.
Ivermectin Prices in APAC
- In China, the Ivermectin Price Index rose quarter-over-quarter in Q1 2026, driven by increased production costs.
- The Ivermectin Production Cost Trend increased during Q1 2026 as the Producer Price Index rose 0.5%.
- The Ivermectin Demand Outlook stabilized in March 2026, supported by a mild 1.0% Consumer Price Index increase.
- Industrial Production grew 5.7% in March 2026, ensuring abundant supply and preventing Ivermectin Price Index spikes.
- Retail sales grew 1.7% while unemployment reached 5.4% in March 2026, softening retail companion animal demand.
- Consumer confidence hit 91.6 in February 2026, while the Manufacturing Index expanded during March 2026.
- Corn starch fermentation feedstock costs for Ivermectin strengthened in Q1 2026 due to firmer domestic values.
- Export volumes of Ivermectin to South Asian markets surged significantly during the Q1 2026 period.
- The Ivermectin Price Forecast remained firm in Q1 2026 as domestic pork and poultry output expanded.
Why did the price of Ivermectin change in March 2026 in APAC?
- Corn starch fermentation feedstock costs strengthened in Q1 2026, pushing overall Ivermectin manufacturing expenses upward.
- Energy and logistics costs for fermentation facilities inched up during Q1 2026, adding price pressure.
- Veterinary antiparasitic demand strengthened in Q1 2026, driven by expanded domestic poultry and pork production.
Ivermectin Prices in Europe
- In Germany, the Ivermectin Price Index fell quarter-over-quarter in Q1 2026, driven by easing upstream production costs.
- The Ivermectin Production Cost Trend declined as producer prices dropped 0.2% in March 2026, softening feedstock expenses.
- Despite a 2.7% CPI rise in March 2026, energy costs for wet-milling glucose feedstocks remained structurally elevated.
- Stagnant industrial production at 0.0% in February 2026 aligned with abundant standard soybean feedstock supply availability.
- The Ivermectin Demand Outlook remained steady, supported by a 0.7% retail sales growth in February 2026.
- A stable 4.2% unemployment rate in February 2026 sustained pharmaceutical grade glucose demand throughout Q1 2026.
- The manufacturing index expanded in March 2026, while European ethanol solvent inventories remained balanced amid restrained trading.
- Negative consumer confidence at -24.7 in March 2026 kept the Ivermectin Price Index suppressed despite discounted imports.
- The Ivermectin Price Forecast reflected downward pressure in Q1 2026 due to persistent soybean fermentation input oversupply.
Why did the price of Ivermectin change in March 2026 in Europe?
- Ethanol extraction solvent costs declined in Q1 2026 amid discounted import offers and improved logistics.
- Soybean-derived fermentation feedstock costs softened significantly following robust global crushing volumes throughout the Q1 2026 period.
- Producer prices dropped 0.2% in March 2026, allowing lower production costs to pass down supply chains.
For the Quarter Ending December 2025
Ivermectin Prices in North America
- In the United States, the Ivermectin Price Index rose in Q4 2025, influenced by increased chemical selling prices in October 2025.
- Ivermectin production costs increased, with CPI rising 2.7% in December 2025 and PPI 3.0% in November 2025.
- Ivermectin demand outlook was supported by a 2.0% industrial production rise in December 2025, especially in agriculture.
- Energy costs for Ivermectin production climbed, with US natural gas spot prices revised upward for Q4 2025.
- US chemicals output contracted in October 2025, contributing to supply fragility for Ivermectin in 2025.
- Retail sales increased 3.3% in November 2025, indirectly supporting Ivermectin demand in pet care and health.
- US pharmaceutical exports and imports both declined substantially in October 2025, impacting Ivermectin trade flows.
- Consumer confidence, at 89.1 in December 2025, indicated a cautious outlook for discretionary spending.
Why did the price of Ivermectin change in December 2025 in North America?
- Rising input costs were evident from 2.7% CPI year-over-year in December 2025.
- Producer Price Index increased 3.0% in November 2025, indicating higher manufacturing expenses.
- US natural gas spot prices revised upward for Q4 2025, increasing energy production costs.
Ivermectin Prices in APAC
- In China, Ivermectin Price Index fell in Q4 2025, due to producer price deflation and weak domestic demand.
- Ivermectin production costs declined in December 2025, as the Producer Price Index fell 1.9% year-over-year.
- Demand for Ivermectin was supported by a 5.2% rise in industrial production in December 2025.
- Weak domestic demand in Q4 2025, with retail sales growing 0.9% in December, impacted consumption.
- China's Manufacturing Index expanded in December 2025, signaling broader industrial sector growth.
- Ivermectin price trends in Q4 2025 were influenced by structural oversupply in China's chemical industry.
- Medicine exports, including active pharmaceutical ingredients, steadily increased in China through November 2025.
- Raw material inventories declined in October 2025, while industrial electricity prices remained stable in Q4 2025.
- Stable inflation (CPI 0.8% in December 2025) and moderate unemployment (5.1%) did not significantly boost consumer spending.
Why did the price of Ivermectin change in December 2025 in APAC?
- Producer Price Index declined 1.9% in December 2025, reducing Ivermectin production costs.
- Weak domestic demand, with retail sales growing 0.9% in December 2025, pressured Ivermectin prices.
- Structural oversupply in China's chemical industry during 2025 contributed to downward price trends.
Ivermectin Prices in Europe
- In Germany, the Ivermectin Price Index fell quarter-over-quarter in Q4 2025, due to weak demand and declining industrial producer prices.
- Ivermectin production costs declined in December 2025, as the Producer Price Index (PPI) decreased by 2.5% year-over-year.
- Demand outlook for Ivermectin weakened in Q4 2025, with chemical industry domestic and export orders trending weak.
- Consumer confidence was significantly negative at -17.5 in December 2025, despite CPI rising 1.8% year-over-year.
- The Manufacturing Index indicated a contracting trend in December 2025, signaling a slowdown in overall industrial activity.
- Industrial production grew modestly by 0.8% in October 2025; retail sales increased 1.1% in November 2025.
- High energy and raw material costs persisted for Germany's chemical industry in October 2025, influencing production expenses.
- Rising import pressures and Chinese overcapacity exerted downward pressure on Ivermectin prices in Q4 2025.
Why did the price of Ivermectin change in December 2025 in Europe?
- Producer Price Index declined 2.5% year-over-year in December 2025, lowering input costs for Ivermectin production.
- Weak domestic and export orders for German chemicals dampened Ivermectin demand throughout Q4 2025.
- Low consumer confidence at -17.5 in December 2025 affected discretionary spending on related healthcare products.
For the Quarter Ending September 2025
Ivermectin Prices in North America
- In the United States, the Ivermectin Price Index rose quarter-over-quarter in Q3 2025, driven by increased production costs and declining chemical output.
- Ivermectin production costs increased, influenced by a 2.6% year-over-year rise in PPI in August 2025 and elevated energy costs.
- Demand for Ivermectin faced headwinds from a 3.0% year-over-year CPI increase and declining consumer confidence in September 2025.
- Despite weak overall chemical demand, retail sales increased 5.42% year-over-year in September 2025, supporting some end-use markets.
- Chemical industry inventories shrank in Q3 2025 due to accelerating destocking, impacting overall supply dynamics.
- Industrial production grew only 0.1% year-over-year in September 2025, reflecting subdued activity and a decline in chemical output.
- Foreign orders for the chemical industry declined in Q3 2025, alongside a fall in US exports in July 2025.
- The unemployment rate of 4.3% in September 2025 indicated a stable labor market, influencing labor costs for manufacturers.
Why did the price of Ivermectin change in September 2025 in North America?
- Increased input and raw materials costs, alongside elevated energy prices, drove Ivermectin production expenses.
- A 2.6% year-over-year PPI increase in August 2025 signaled rising producer costs, impacting Ivermectin.
- Declining chemical output in September 2025, coupled with shrinking inventories, tightened supply.
Ivermectin Prices in APAC
- In China, the Ivermectin Price Index fell quarter-over-quarter in Q3 2025, driven by persistent overcapacity and contracting manufacturing activity.
- Ivermectin production costs declined in Q3 2025, as PPI fell by 2.3% in September 2025 and energy costs eased.
- Demand for Ivermectin was supported by 6.5% industrial production growth in September 2025 and a thriving pharmaceutical industry.
- The veterinary medicine market experienced growth in Q3 2025, bolstering Ivermectin demand despite consumer confidence at 89.6.
- Retail sales rose by 3.0% in September 2025, yet CPI fell by 0.3%, indicating mixed signals for Ivermectin demand.
- Stable unemployment at 5.2% in September 2025 sustained consumer spending on healthcare and pet care products.
- Persistent overcapacity in China's chemical industry exerted downward pressure on Ivermectin prices during Q3 2025.
- Corn starch feedstock costs stabilized in Q3 2025, influenced by improved logistics and easing energy costs.
Why did the price of Ivermectin change in September 2025 in APAC?
- Falling PPI by 2.3% in September 2025 reduced raw material costs for Ivermectin producers.
- Contracting Manufacturing Index in September 2025 signaled weaker industrial demand for chemical inputs.
- Persistent overcapacity in China's chemical industry during Q3 2025 exerted downward pressure on prices.
Ivermectin Prices in Europe
- In Germany, the Ivermectin Price Index fell quarter-over-quarter in Q3 2025, influenced by contracting industrial activity.
- Ivermectin production costs faced persistent industry-wide increases in Q3 2025, despite moderating European natural gas prices.
- Ivermectin demand outlook weakened in Q3 2025, as the Manufacturing Index contracted and industrial production declined.
- Inflationary pressures, indicated by a 2.4% year-over-year CPI in September 2025, affected operational expenses.
- Producer input costs showed deflationary trends, with PPI declining by 1.7% year-over-year in September 2025.
- Significantly negative consumer confidence of -23.6 in September 2025 suggested cautious spending, pressuring demand.
- German chemical and pharmaceutical industry production declined in Q3 2025, with capacity utilization below profitability.
- International sales for the German chemical and pharmaceutical industry weakened significantly in Q3 2025.
- A low unemployment rate of 3.9% in September 2025 indirectly supported consumer spending capacity.
Why did the price of Ivermectin change in September 2025 in Europe?
- Contracting industrial activity, with the Manufacturing Index contracting in September 2025, reduced demand.
- Weakening international sales for German chemical products in Q3 2025 increased supply pressure.
- Persistent high industry costs in Q3 2025 maintained upward pressure on production expenses.
